Switch theme
Sign up to access all valuation multiples
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
1993
149
LTM Revenue $3.6M
LTM EBITDA -$160M
-$67.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IGM Biosciences has a last 12-month revenue of $3.6M and a last 12-month EBITDA of -$160M.
In the most recent fiscal year, IGM Biosciences achieved revenue of $2.7M and an EBITDA of -$199M.
IGM Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IGM Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $2.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$255M | -$199M | XXX | XXX | XXX |
| EBITDA Margin | -11980% | -7446% | XXX | XXX | XXX |
| Net Profit | -$221M | -$246M | XXX | XXX | XXX |
| Net Margin | -10380% | -9198% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, IGM Biosciences's stock price is $1.
IGM Biosciences has current market cap of $71.1M, and EV of -$67.5M.
See IGM Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$67.5M | $71.1M | XXX | XXX | XXX | XXX | $-2.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, IGM Biosciences has market cap of $71.1M and EV of -$67.5M.
IGM Biosciences's trades at -18.9x LTM EV/Revenue multiple, and 0.4x LTM EBITDA.
Analysts estimate IGM Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for IGM Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$67.5M | XXX | XXX | XXX |
| EV/Revenue | -25.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIGM Biosciences's NTM/LTM revenue growth is 85%
IGM Biosciences's revenue per employee for the last fiscal year averaged $18K, while opex per employee averaged $1.4M for the same period.
Over next 12 months, IGM Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate IGM Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for IGM Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7446% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -7361% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $18K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1881% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6004% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 7886% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IGM Biosciences acquired XXX companies to date.
Last acquisition by IGM Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . IGM Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was IGM Biosciences founded? | IGM Biosciences was founded in 1993. |
| Where is IGM Biosciences headquartered? | IGM Biosciences is headquartered in United States of America. |
| How many employees does IGM Biosciences have? | As of today, IGM Biosciences has 149 employees. |
| Who is the CEO of IGM Biosciences? | IGM Biosciences's CEO is Ms. Mary Beth Harler. |
| Is IGM Biosciences publicy listed? | Yes, IGM Biosciences is a public company listed on NAS. |
| What is the stock symbol of IGM Biosciences? | IGM Biosciences trades under IGMS ticker. |
| When did IGM Biosciences go public? | IGM Biosciences went public in 2019. |
| Who are competitors of IGM Biosciences? | Similar companies to IGM Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IGM Biosciences? | IGM Biosciences's current market cap is $71.1M |
| What is the current revenue of IGM Biosciences? | IGM Biosciences's last 12-month revenue is $3.6M. |
| What is the current EBITDA of IGM Biosciences? | IGM Biosciences's last 12-month EBITDA is -$160M. |
| What is the current EV/Revenue multiple of IGM Biosciences? | Current revenue multiple of IGM Biosciences is -18.9x. |
| What is the current EV/EBITDA multiple of IGM Biosciences? | Current EBITDA multiple of IGM Biosciences is 0.4x. |
| What is the current revenue growth of IGM Biosciences? | IGM Biosciences revenue growth between 2023 and 2024 was 26%. |
| Is IGM Biosciences profitable? | Yes, IGM Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
